Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai

Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and E…

2024 ASCO® Annual Meeting Insights Hub

K. Rogers, J. Woyach

Venetoclax vs. BTKis in CLL Treatment

City of Hope

A. Danilov

Impact of Ibrutinib Dose Modifications in CLL

Ruemu Birhiray

Guideline-Based Treatment Approaches in CLL

Farrukh Awan

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Managing Cardiotoxicities in TKI Therapy for CLL: Atrial Fibrillatio…

Avirup Guha

Guidelines for Dose Reduction of Ibrutinib in CLL

Matthew McKinney

Managing Cardiotoxicities in BTKi Treatment for CLL: Atrial Fibrilla…

Lydia Scarfò

Current Options for Finite-Duration Therapy With BTKis in CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

EHA 2024 Insights: SEQUOIA Trial Arm D - Zanubrutinib + Venetoclax f…

Insights from 2024 EHA Annual Meeting

P. Ghia

State-of-the-Art in CLL Treatment

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Cuneo